AVXL
Anavex Life Sciences Corp.
NASDAQ · Healthcare · Biotechnology · US
$2.86
+0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 20.3M | 37.6M | 41.8M | 43.7M | 37.9M |
| SG&A Expense | 10.4M | 13.8M | 11.0M | 12.0M | 13.1M |
| General & Admin Expense | 8.1M | 13.8M | 11.0M | 12.0M | 13.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 30.6M | 51.4M | 52.9M | 55.8M | 51.0M |
| Cost and Expenses | 30.6M | 51.4M | 52.9M | 55.8M | 51.0M |
| Operating Income (EBIT) | (30.6M) | (51.4M) | (52.9M) | (55.8M) | (51.0M) |
| Non-Operating | |||||
| Interest Income | 3.1M | 4.7M | 7.3M | 6.5M | 947.0K |
| Interest Expense | — | — | — | 964.0K | — |
| Net Interest Income | 3.1M | 4.7M | 7.3M | 5.6M | 947.0K |
| Other Non-Op Income/Expense | 6.6M | 5.0M | 9.9M | 8.3M | 3.4M |
| Non-Operating Income (excl Interest) | (8.8M) | (5.0M) | (9.9M) | (9.2M) | (3.4M) |
| EBT (Pre-Tax Income) | (24.0M) | (46.4M) | (43.0M) | (47.5M) | (47.6M) |
| Income Tax Expense | 9.0K | — | — | — | 358.0K |
| Bottom Line | |||||
| Net Income | (24.0M) | (46.4M) | (43.0M) | (47.5M) | (48.0M) |
| Earnings from Cont. Ops | (24.0M) | (46.4M) | (43.0M) | (47.5M) | (48.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.0M) | (46.4M) | (43.0M) | (47.5M) | (48.0M) |
| Per Share | |||||
| Basic EPS | ($0.26) | ($0.54) | ($0.52) | ($0.60) | ($0.62) |
| Diluted EPS | ($0.26) | ($0.54) | ($0.52) | ($0.60) | ($0.62) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 91.5M | 85.3M | 83.5M | 79.8M | 76.9M |
| Diluted Shares Outstanding | 91.5M | 85.3M | 83.5M | 79.8M | 76.9M |
| Profitability Metrics | |||||
| EBITDA | (21.8M) | (46.4M) | (43.0M) | (46.5M) | (47.6M) |
| D&A | — | — | — | — | — |
| EBIT | (21.8M) | (46.4M) | (43.0M) | (46.5M) | (47.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026